Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 28 · below the Ichimoku cloud · RSI 27 (oversold) · MACD below its signal
| 3.54 | 52-week high | +197.48% |
| 2.69 | Previous month high | +126.05% |
| 1.58 | Previous month low | +32.77% |
| 1.51 | Previous week high | +26.89% |
| 1.46 | R3 (classic) | +22.41% |
| 1.40 | R2 (classic) | +17.93% |
| 1.35 | Previous day high | +13.45% |
| 1.30 | R1 (classic) | +8.96% |
| 1.24 | Pivot | +4.48% |
| 1.19 | Previous day low | +0.00% |
| 1.19 | Previous week low | +0.00% |
| 1.19 | Price now | |
| 1.14 | S1 (classic) | −4.48% |
| 1.08 | S2 (classic) | −8.96% |
| 0.9767 | S3 (classic) | −17.93% |
| 0.7600 | 52-week low | −36.13% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.0M | 0.00% | 637.62K | −2.9% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EQ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.78 per share. | 14.6K | $11.45K |
| Jun 4, 2026 | Connelly StephenPresident | Sale at price 2.94 - 3.16 per share. | 231K | $723.83K |
| Jun 4, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 2.93 per share. | 14.6K | $42.74K |
| May 27, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | 95.8K | $73.95K |
| May 27, 2026 | Tom PennyOfficer | Conversion of Exercise of derivative security at price 0.78 per share. | 65K | $51.02K |
| May 27, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 2.70 - 2.98 per share. | 95.8K | $267.21K |
| May 27, 2026 | Tom PennyOfficer | Sale at price 2.95 per share. | 65K | $191.75K |
| Mar 12, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.78 per share. | 120.3K | $94.44K |
| Mar 12, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 2.50 per share. | 120.3K | $300.82K |
| Mar 8, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.78 per share. | 152.4K | $119.60K |
| Mar 8, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 2.00 per share. | 181.2K | $362.44K |
| Feb 18, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | 185.9K | $141.75K |
| Feb 18, 2026 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | 185.9K | $141.75K |
| Feb 18, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 1.74 - 1.78 per share. | 185.9K | $328.10K |
| Feb 18, 2026 | Zedelmayer ChristineChief Operating Officer | Sale at price 1.74 - 1.78 per share. | 185.9K | $328.10K |
| Jan 7, 2026 | Tom PennyOfficer | Sale at price 1.29 per share. | 6.5K | $8.43K |
| Dec 22, 2025 | Zedelmayer ChristineChief Operating Officer | Conversion of Exercise of derivative security at price 0.78 per share. | 100K | $78.50K |
| Dec 22, 2025 | Zedelmayer ChristineChief Operating Officer | Sale at price 1.50 per share. | 100K | $150.00K |
| Dec 14, 2025 | Zedelmayer ChristineChief Operating Officer | Sale at price 1.31 - 1.34 per share. | 35.7K | $47.49K |
| Nov 24, 2025 | Zedelmayer ChristineChief Operating Officer | Sale at price 0.95 - 0.98 per share. | 8.1K | $7.70K |
TimeframesDown on the hourly and daily, mixed on the weekly and monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.4 | 28.2 | 9.9 | 2.0 | 42.2 | 10.3 | -31.2 | 3.2 | -28.2 | -27.0 | −23.2% | ||
| 2025 | -14.7 | 18.8 | -48.7 | 7.7 | -7.1 | -17.9 | 21.9 | 346.2 | -17.8 | -1.4 | -36.2 | 72.2 | +106.7% |
| 2024 | 11.1 | 211.2 | -7.2 | -35.5 | 0.7 | -54.0 | 8.7 | 42.7 | -22.4 | 3.6 | -12.8 | 0.0 | +4.2% |
| 2023 | 1.9 | -14.8 | -20.7 | -15.1 | 0.0 | 21.0 | -1.3 | 9.5 | -8.6 | -31.1 | 13.7 | 24.1 | −32.1% |
| 2022 | 4.0 | -4.1 | -16.2 | -22.5 | 2.5 | -18.4 | 8.3 | 23.1 | -18.4 | -16.2 | -10.8 | -36.1 | −71.9% |
| 2021 | 7.1 | 23.0 | 1.4 | -9.4 | 1.2 | -10.2 | -8.0 | 13.5 | 10.9 | -7.5 | -16.8 | -28.2 | −29.5% |
| 2020 | 35.2 | 5.3 | -43.7 | 0.7 | 26.4 | -14.5 | 227.1 | -39.0 | -2.0 | 10.1 | -18.1 | 2.9 | +58.3% |
| 2019 | 7.7 | -10.5 | 1.7 | -22.0 | 3.4 | -12.2 | -27.6 | -5.9 | -1.6 | -6.1 | -9.0 | 4.0 | −58.6% |
| 2018 | 17.1 | -50.2 | −41.7% |
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Buy / hold / sell counts